This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutStorage and handlingVial sizes and NDC numbersBiochemical composition and manufacturingDosing & Infusion RatesDosing & 
Infusion Rates
CIDPDosing and administrationInfusion rate chartInfusion rate calculatorPIDosing and administrationInfusion rate chartInfusion rate calculatorcITPDosing and administrationInfusion rate chartInfusion rate calculator
EfficacyEfficacyCIDPStudy designINCAT responder ratesSupporting efficacy endpointsRescue dosingPatient profilesPIStudy designsPrimary endpoint, supporting efficacy endpoints, and safety assessmentsPatient profilescITPStudy design, primary endpoint, and supporting efficacy endpointsSafety & TolerabilitySafety & TolerabilityCIDPPIcITPSupportSupportMaterialsVideosCIDP Warranty ProgramPfizer PANZYGA Co-Pay Program for patientsPfizer IGuideTMIg Companion patient mobile appFrequently asked questionsRequest a representative
Prescribing Information, including BOXED WARNINGIndicationsImportant Safety Information
The Pfizer Pledge Warranty Program* for adult patients with CIDP starting PANZYGA

As part of its commitment to patients with CIDP, Pfizer is proud to offer the Pfizer Pledge Warranty Program* for adult patients with CIDP starting PANZYGA. With this program, eligible patients can get their out-of-pocket drug costs for PANZYGA refunded. See below to learn more.

Not available for residents of Puerto Rico.Terms and conditions/eligibility requirements apply. See below for full terms and conditions.Single treatments may be given over 1 or more days.Downloadable documentsPatient Warranty Claim FormThe patient can start the claims process by downloading, filling out, and submitting this form. The call center is open Monday through Friday, 8 AM to 8 PM ET. The call center representative can walk the patient through the forms and provide instructions on how to complete them. Download form LoadingPatient Declarations and Authorizations FormThis form will need to be read, signed, and submitted by the patient in order to process their claim. Download form LoadingHealthcare Provider Attestation FormIf the patient is eligible for the warranty, please fill out and submit this form, or give the signed form to the patient to submit. Download form LoadingPharmacy Provider Attestation FormIf the patient is eligible for the warranty, please fill out and submit this form, or give the signed form to the patient to submit. Download form LoadingTerms and Conditions for Patients

Pfizer, Inc. (referred to as “us,“ “we” and similar terms) is proud to offer the Pfizer Pledge Warranty Program for PANZYGA (the “Program“) to each Patient (referred to as “you,“ “your“ and similar terms) who meets the Eligibility Requirements and follows the Program Procedures described below, subject to all the terms and conditions in this document (the “Terms“). You should carefully review these Terms. 

Overview of Program

For Patients who meet the Eligibility Requirements, Pfizer will refund the out-of-pocket amount that you paid for up to the first 4 Treatments of PANZYGA for the chronic inflammatory demyelinating polyneuropathy (CIDP) indication, up to a maximum of $16,500 per treatment. The total, per patient, Program refund shall not exceed $50,000 (the “Maximum”). Treatment is defined as the total prescribed dose, which may be administered by a healthcare provider over one or more days. If your commercial insurance and/or other payers (“Your Plan(s)”) paid for all or a portion of the cost of PANZYGA, Pfizer will, on your behalf, refund Your Plan(s) the Average Sales Price as calculated by Pfizer up to the Maximum, less documented out-of-pocket payments provided by you or on your behalf. Payments to all parties must be equal to or less than the cost paid by each party and may reset Your Plan(s)’s out-of-pocket deductible cost in accordance with Your Plan(s)’s benefit design. The order of priority of Warranty payments is first to you and then to Your Plan that is primary and then to Your Plan(s) that are secondary as determined by information provided by you and the documented proof of payment that you provide to us. You are responsible for submitting proof of payment for you and for Your Plan(s). All claims payments will be reported to Your Plan(s).

Medication Eligible for the Program
PANZYGA
[Immune Globulin Intravenous (Human) - ifas]

Eligibility Requirements

The Pfizer Pledge Warranty Program is available to adult, cash-paying or commercially insured patients. Patients are not eligible for the program if their PANZYGA was covered, in whole or in part, by Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Commercially insured or cash-paying adult patients must satisfy all of the following criteria in order to be eligible to use the Program:

  1. You are a resident of the 50 United States of America or the District of Columbia. The Program is void for any request made by anyone living outside the 50 United States or the District of Columbia.
  2. You were prescribed PANZYGA by your healthcare provider to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
  3. You used PANZYGA on-label according to the instructions provided by your healthcare provider.
  4. You have not used another Immunoglobulin product in the past 12 months.
  5. You discontinued PANZYGA for clinical reasons defined at the discretion of the healthcare provider. Discontinuation or switching to another Ig (intravenous or subcutaneous) product due to patient choice, affordability, or for a non-clinical reason does not qualify for the Program.
  6. You must discontinue using PANZYGA prior to the administration of the fifth treatment of PANZYGA.
  7. PANZYGA treatment administered as a hospital inpatient is not eligible for the Warranty.
  8. You are not eligible to participate in this Program if you are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  9. Your first treatment of PANZYGA must be administered on or after July 1, 2022, and on or before June 30, 2024 (the “Coverage Period”).
  10. Only PANZYGA sold by Pfizer will be eligible for this warranty. You may be able to identify this through the NDC codes listed in the “Medication Eligible for the Program” section.

Costs other than for the drug will not be reimbursed (i.e., administration costs).

You must submit all Claims Information (as described below) within 180 days following the administration date of your last treatment of PANZYGA.

Benefit Request Process

  1. To be eligible for a refund under this Program, you must satisfy the requirements and submit the information below (the “Claims Information”), 180 days following the date of your last treatment of PANZYGA. Call 1-800-276-0726 and a representative will provide you with a Patient Warranty Claim Form, a Patient Declarations and Authorizations Form, a Healthcare Provider Attestation Form, and a Pharmacy Attestation Form, or these forms may be downloaded from www.panzygainfo.com.
  2. You will need to provide a copy/photo of the following: (1) both sides of your insurance card(s) for both prescription and medical benefit insurance, (2) the Explanation of Benefits (EOB) for each treatment from your Health Insurer(s).
  3. You will then need to return a fully completed and signed (1) Patient Warranty Claim Form, (2) Patient Declarations and Authorizations Form, (3) Healthcare Provider Attestation Form, and (4) Pharmacy Attestation Form in accordance with their instructions, which will include the following information:
    1. Patient Warranty Claim Form:
      • Your name, date of birth, phone number, address, gender, and email address
      • Prescribing healthcare provider name, phone number, and address
      • For each treatment, the dispensing pharmacy name, phone number, and address
      • ​​​​​​For each treatment, Your Plan(s)’s information and amounts paid by Your Plan(s), including the following:
        • For each primary insurer, secondary insurer and prescription insurer: the insurance type, insurer name, phone number, address, policy beneficiary ID number, group number, policyholder name, policyholder relationship, and policyholder date of birth
    2. Patient Declarations and Authorizations Form, which includes your:
      • Consent for the Pfizer Pledge
      • Consent to receive communication from our representative to process your claim
      • Authorization to share health information to process your claim
      • Acknowledgment of laws
    3. Healthcare Provider Attestation Form, completed and signed by your prescribing healthcare provider, which includes the following information:
      • Your name and date of birth
      • Prescribing healthcare provider name, phone number and address
      • Prescribing healthcare provider’s attestation that PANZYGA was prescribed for on-label use for the chronic inflammatory demyelinating polyneuropathy (CIDP) indication, and the clinical rationale for discontinuance of PANZYGA (no confirmatory documentation required)
      • Attestation that you have discontinued PANZYGA prior to the fifth treatment of PANZYGA
    4. Pharmacy Attestation Form, completed and signed by the pharmacy dispensing PANZYGA or the clinic infusing PANZYGA, which includes the following information: ​​​​​
      • Your name and date of birth
      • The PANZYGA treatment dates
      • The number of vials of each strength of PANZYGA dispensed for each treatment date
      • For each treatment date: the amount of money you paid out-of-pocket, the amount of financial assistance from the Pfizer PANZYGA Co-Pay Program, and the amount of co-pay assistance from any other source other than the Pfizer PANZYGA Co-pay Program
      • The number of Pfizer vials of PANZYGA that were dispensed (Pharmacy) or infused (Clinic)
      • The amount of money documented on the form was collected
      • Federal programs (including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”) were not billed for PANZYGA
  4. If your Claims Information passes the verification process, we will notify you via telephone or email that you have been approved for coverage.
  5. If your Claims Information does not pass the verification process, we will notify you via email that your request has been denied and the email will include the reason for the denial (such as incomplete information, mismatched information, etc.). You will be given the opportunity to resubmit your Claims Information within 30 days of the email notification.
Additional Terms and Conditions

By submitting your Claims Information under the Program, you are representing and warranting that you took the medication in accordance with the instructions that were provided by your prescribing healthcare provider.
  • We reserve the right to modify the processes, procedures, parameters, or other terms of the Program, or terminate the Program entirely, at any time, without prior notice to you. If we terminate the Program, we will: continue to honor valid warranty claims for patients whose initial dose of PANZYGA occurred prior to the termination date of the program. The current status of the Program and applicable terms are available at www.panzygainfo.com
  • We are refunding payments under this Program to you and Your Plan(s) based on the information provided by you. You are responsible for resolving any disagreements related to reimbursements made by us, on Your behalf, to Your Plan(s)

LIMITATION OF LIABILITY

IN NO EVENT, UNDER ANY CAUSE OF ACTION OR THEORY OF LIABILITY, SHALL PFIZER, ITS DISTRIBUTORS OR SUPPLIERS BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, OF ANY NATURE WHATSOEVER, ARISING OUT OF OR IN CONNECTION WITH THE PROGRAM, EVEN IF PFIZER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

NOTWITHSTANDING ANY DAMAGES THAT YOU MIGHT INCUR FOR ANY REASON WHATSOEVER, INCLUDING, WITHOUT LIMITATION, ALL DAMAGES REFERENCED HEREIN AND ALL DIRECT OR GENERAL DAMAGES IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, THE ENTIRE AGGREGATE LIABILITY OF PFIZER AND ANY OF ITS DISTRIBUTORS AND/OR SUPPLIERS SHALL BE LIMITED TO THE MAXIMUM AMOUNT SET FORTH ABOVE FOR THE PRODUCT THAT IS SUBJECT TO THE PROGRAM. SOME STATES AND/OR JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATIONS OR EXCLUSIONS MAY NOT APPLY TO YOU. THE LIMITATIONS OF LIABILITY SET FORTH ABOVE SHALL APPLY TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW. 

ARBITRATION: Read the following arbitration provision (“Provision”) carefully. It limits certain of your rights, including your right to obtain relief or damages through court action.

To begin Arbitration, either you or we must make a written demand to the other party for Arbitration for the applicable claim ("Claim"). The Arbitration will take place before a single arbitrator. It will be administered in keeping with the Expedited Procedures of the Commercial Arbitration Rules ("Rules") of the American Arbitration Association ("AAA") in effect when the Claim is filed. You may get a copy of the AAA's Rules by visiting www.adr.org. The filing fees to begin and carry out Arbitration will be shared equally between you and us. This does not prohibit the arbitrator from giving the winning party their fees and expenses for the Arbitration. Unless you and we agree, the Arbitration will take place in the county and state where you live. The Federal Arbitration Act, 9 U.S.C. Ch. 1, et seq., will govern, and not any state law on Arbitration. YOU AGREE AND UNDERSTAND THAT this Arbitration Provision means that you give up your right to go to court on any Claim covered by this provision. You also agree that any Arbitration proceeding will only consider your Claim. Claims by, or on behalf of, other individuals will not be arbitrated in any proceeding that is considering your Claim. THE DEGREE TO WHICH ARBITRATION CAN BE USED AS A DISPUTE RESOLUTION PROCESS FOR CONSUMER CLAIMS VARIES FROM STATE TO STATE, SO THIS ARBITRATION PROVISION MAY NOT APPLY TO YOU, DEPENDING ON YOUR STATE OF RESIDENCE. In the event this Arbitration provision is not approved by the appropriate state regulatory agency, and/or is stricken, severed, or otherwise deemed unenforceable by a court of competent jurisdiction, you and we specifically agree to waive and forever give up the right to a trial by jury. Instead, in the event any litigation arises between you and us, any such lawsuit will be tried before a judge, and a jury will not be impaneled or struck.

Support Request a representative Request here Loading Ig Companion: Free mobile app to help support patients Learn more about the app Loading Access materials and videos Access here Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-PAN-USA-0828
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-PAN-USA-0594
INDICATIONS AND USAGE PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE IMPORTANT SAFETY INFORMATION
  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
Contraindications PANZYGA is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity. Warnings and Precautions Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure. Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving PANZYGA. Aseptic meningitis syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). Monitor blood pressure prior to, during, and following PANZYGA infusion. Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload. PANZYGA is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent. Adverse Reactions PI – The most common adverse reactions (>5% study subjects) were headache, nausea, fever, fatigue, and abdominal pain. cITP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, nausea, vomiting, dizziness, and anemia. CIDP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, dermatitis, and blood pressure increase. The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for PANZYGA. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. PANZYGA® is a registered trademark of Octapharma AG. Please click here for Full Prescribing Information, including BOXED WARNING. Helix ImageINDICATIONS 
AND USAGE
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.